Vertex Pharmaceuticals VRTX
NASDAQ VRTX
$535.17 +10.65 (+2.03%)
At close: Oct 22, 2026 · 4:00 PM EDT

Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017)

Updated

Vertex Pharmaceuticals (VRTX) recorded Short-Term Debt repayments of $300 million in FY2017.

Analysis

Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 6.63 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Vertex Pharmaceuticals 135.25 Bn 107.26 Bn 2.84 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 300.00 Mn
API Access

Vertex Pharmaceuticals Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=VRTX&period=max&api_key=YOUR_API_KEY